The stock of Protalix BioTherapeutics Inc. (AMEX:PLX) last traded at $2.12, up 3.92% from the previous session.
Data from the available sources indicates that Protalix BioTherapeutics Inc. (AMEX:PLX) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $16.00, we find $16.00. Given the previous closing price of $2.04, this indicates a potential upside of 684.31 percent. PLX stock price is now -9.98% away from the 50-day moving average and 37.00% away from the 200-day moving average. The market capitalization of the company currently stands at $145.50M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $16.00 as their price target over the next twelve months.
In other news, Schwartz Aharon, Director bought 110,000 shares of the company’s stock on Jan 03. The stock was bought for $155,815 at an average price of $1.42. Upon completion of the transaction, the Director now directly owns 174,000 shares in the company, valued at $0.37 million. A total of 11.99% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PLX stock. A new stake in Protalix BioTherapeutics Inc. shares was purchased by CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. during the first quarter worth $336,000. MARSHALL WACE, LLP invested $319,000 in shares of PLX during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Protalix BioTherapeutics Inc. valued at approximately $184,000. XTX TOPCO LTD acquired a new stake in PLX for approximately $72,000. TWO SIGMA SECURITIES, LLC purchased a new stake in PLX valued at around $44,000 in the second quarter. In total, there are 30 active investors with 19.60% ownership of the company’s stock.
With an opening price of $2.0500 on Monday morning, Protalix BioTherapeutics Inc. (AMEX: PLX) set off the trading day. During the past 12 months, Protalix BioTherapeutics Inc. has had a low of $1.00 and a high of $3.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.80, and a quick ratio of 1.10. The fifty day moving average price for PLX is $2.3604 and a two-hundred day moving average price translates $1.5527 for the stock.
The latest earnings results from Protalix BioTherapeutics Inc. (AMEX: PLX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.15 by 0.08. This compares to -$0.05 EPS in the same period last year. The net profit margin was -38.30% and return on equity was 203.30% for PLX. The company reported revenue of $9.59 million for the quarter, compared to $16.09 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -40.39 percent.
Protalix BioTherapeutics Inc.(PLX) Company Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Leave a Reply